Siegfried Holding AG
SFZN.SW
Swiss Exchange73.90
CHF
+2.10
- -
Siegfried Holding AG
SFZN.SW
(Swiss Exchange)
Recent
price
73.90
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Siegfried Holding AG, founded in 1873 and headquartered in Zofingen, Switzerland, develops and manufactures active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms as a leading global contract development and manufacturing organization (CDMO) for the pharmaceutical industry; its core offerings encompass contract development and production of drug substances including highly potent APIs and controlled substances, as well as drug products such as tablets, capsules, sterile vials, ampoules, cartridges, ointments, and aseptic filling for solid oral, liquid, and biologic formats like vaccines and cell/gene therapies; the company operates 13 production sites across seven countries on three continents, including Switzerland, Germany, France, Spain, Malta, the United States, and China, serving over 500 customers worldwide with approximately 3,800 employees and supplying around 200 FDA-approved APIs that reach up to one billion patients annually. Siegfried conducts business through two primary segments, Drug Substances (APIs and intermediates, contributing about 69% of revenues) and Drug Products (finished dosage forms, around 31%), targeting pharmaceutical and biotechnology firms with integrated services from early-phase process development, optimization, analytical testing, scale-up, registration, commercial manufacturing, packaging, and logistics. In recent developments, Siegfried completed the acquisition in July 2024 of a Wisconsin-based CDMO specializing in early-phase drug substance services to enhance U.S. capabilities and geographic reach; it opened a state-of-the-art quality control lab in Minden, Germany in August 2024, inaugurated cutting-edge labs for DINAMIQS in November 2024 as part of a cGMP viral vector facility for cell and gene therapies operational by end-2025, and launched a new global R&D center for drug substances in Evionnaz, Switzerland in November 2024; the company unveiled its updated strategy EVOLVE+ in October 2024 emphasizing commercial, development, and operational excellence alongside value-accretive M&A, while advancing sustainability with science-based GHG targets, 87% renewable electricity, and a 45.7% absolute carbon reduction since 2020, maintaining distinctions like Dow Jones Sustainability Index Europe membership and MSCI AA rating; in 2024 net sales reached CHF 1,295 million with core EBITDA of CHF 286 million (22.1% margin), and the board proposes a CHF 3.80 per share distribution plus a 1:10 share split at the April 2025 AGM.